SEED Capital sells EpiTherapeutics for € 57 millions
The Danish EpiTherapeutics ApS is developing new cancer drugs with primarily focus on prostate cancer. In the future, the medication may also be used for other clinical areas. This week, it has been announced that SEED Capital sells the company to Gilead Sciences for € 57 millions. “BRIC and the University of Copenhagen deserve a […]